Efektivitas Dan Keamanan Vaksin Covid-19 : Studi Refrensi
Authors (s)
(1) * Setiyo Adi Nugroho  
![](/public/site/images/admin/mail.gif)
        Indonesia
(2)  Indra Nur Hidayat   (Universitas Nurul Jadid, Probolinggo)  
        Indonesia
(*) Corresponding Author
AbstractVarious strategies and development of the Covid-19 vaccine have been carried out for the control of the Covid-19 pandemic. Various vaccines have undergone clinical trials with promising results in various countries. The effectiveness and safety and short- and long-term side effects of vaccines are a major concern in clinical trials in these strategies and developments. Purpose: The purpose of this study is to find out the effectiveness and safety of the Covid-19 vaccine so that it can inform and increase public confidence in the Covid-19 vaccine through a reference study approach. Method: The research method we use here is a reference study using electronic databases through journals from international and national. Google Scholar, science direx, elsiver, Pubmed are used as the main Journal database for this reference study. Results: From the results of reference studies found that all vaccines in clinical trials have promising effectiveness and safety. The Pfizer-BiONTech vaccine is a vaccine that has a good level of effectiveness and safety with a value of 94.6% and does not cause serious side effects. Double-dose vaccination further improves the immune response in younger and older adults. Conclusion: The Covid-19 vaccine in clinical trials all demonstrates promising immunogenicity with varying levels of protective effectiveness and an acceptable safety profile. |
Keywords
Full Text: PDF
Article View
![](/public/site/images/admin/icon-graph.png)
10.33650/jkp.v9i2.2767 |
|
Refbacks
- There are currently no refbacks.
Copyright (c) 2021 Setiyo Adi Nugroho, Indra Nur Hidayat
![Creative Commons License](http://licensebuttons.net/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.